Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Apyx Medical (APYX) over the last 16 years, with Q3 2025 value amounting to $51.3 million.

  • Apyx Medical's Total Liabilities rose 355.59% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.3 million, marking a year-over-year increase of 355.59%. This contributed to the annual value of $50.5 million for FY2024, which is 346.15% down from last year.
  • Per Apyx Medical's latest filing, its Total Liabilities stood at $51.3 million for Q3 2025, which was up 355.59% from $50.7 million recorded in Q2 2025.
  • In the past 5 years, Apyx Medical's Total Liabilities registered a high of $52.3 million during Q4 2023, and its lowest value of $10.9 million during Q1 2021.
  • Over the past 5 years, Apyx Medical's median Total Liabilities value was $25.7 million (recorded in 2023), while the average stood at $30.6 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first crashed by 649.5% in 2021, then skyrocketed by 27418.11% in 2023.
  • Over the past 5 years, Apyx Medical's Total Liabilities (Quarter) stood at $14.7 million in 2021, then dropped by 4.96% to $14.0 million in 2022, then soared by 274.18% to $52.3 million in 2023, then fell by 3.46% to $50.5 million in 2024, then grew by 1.54% to $51.3 million in 2025.
  • Its Total Liabilities was $51.3 million in Q3 2025, compared to $50.7 million in Q2 2025 and $49.5 million in Q1 2025.